/PRNewswire/ Flare Therapeutics Inc., a biotechnology company targeting transcription factors (TF) to discover precision medicines for cancer and other.
First presentation of results from Phase 3 CheckMate -67T trial with subcutaneous formulation of Opdivo to be shared in a late-breaking oral presentation
Four-year data from CheckMate -9ER and.
1. The median overall survival was similar between both groups, 15.2 months in atezolizumab monotherapy vs 13.3 months in chemotherapy, with HR 0.98. 2. Atezolizumab monotherapy was better tolerated, with 16% experiencing grade 3–4 treatment-related adverse events compared to 80% in chemotherapy. Evidence Rating Level: 1 (Excellent) Study Rundown: Cisplatin-based chemotherapy is the standard of
In the phase 3 EV-302/KEYNOTE-A39 clinical trial, the antibody-drug conjugate enfortumab vedotin plus PD-1 inhibitor pembrolizumab nearly doubled both median overall survival and progression-free survival compared with chemotherapy.